Recipharm to communicate new financial targets on Capital Markets Day

Recipharm AB (publ) has continued to grow and will present its strategy for profitable growth moving forward, together with new financial targets from 2020, at today’s Capital Markets Day in Stockholm.

The new financial targets are:

  • Recipharm’s target is to achieve a Compound Annual Growth Rate (CAGR) of at least 11%, with 2019 as base year. The growth will be organic as well as come from acquisitions.
     
  • Recipharm’s target is to achieve an EBITA margin of at least 12% each year, measured as profit before financial items, tax and amortisation of intangible assets attributable to acquisitions, adjusted for non-recurring items and in relation to net sales.
     
  • Recipharm’s target is to achieve a return on operating capital of 10%, defined as EBITA divided by operating capital.

Thomas Eldered, CEO, comments:” Recipharm’s strategy is firm, we have a good foundation for continued long-term and competitive value creation. Our decentralised business model promotes the entrepreneurial spirit in which strong leaders develop and drive our operating companies to continuously improve. Our financial targets guide our work to continued profitable growth”.



Contact information
Thomas Eldered, CEO, telephone: +46 8 602 52 10
Tobias Hägglöv, CFO,
ir@recipharm.com, +46 8 602 52 00

This information is information that Recipharm AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, on 18 November 2019, at 07:45 CET.

 

About Recipharm
Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical industry employing almost 7,000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, and pharmaceutical product development. Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. Recipharm’s turnover is approximately SEK 7.2 billion. The company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden. The Recipharm B-share (RECI B) is listed on Nasdaq Stockholm.

For more information on Recipharm and our services, please visit www.recipharm.com